Yan Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Jin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Qiang Zhao
Department of Pediatric Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Centre for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
6 shared publications Baocheng Gong
Department of Pediatric Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Centre for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
5 shared publicationsTongyuan Qu
Department of Pediatric Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Centre for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
4 shared publicationsZian Song
Department of Pediatric Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Centre for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
4 shared publicationsChaoyu Wang
Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
2 shared publicationsChong Chen
Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119516
Corrigendum to “Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2” [Biomed. Pharmacother. 177 (2024) 117126]
- 14 May 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119516
Open AccessCorrigendum to “Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2” [Biomed. Pharmacother. 177 (2024) 117126]
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 30
TFAP2D drives neuroblastoma progression: a disulfidptosis-fatty acid metabolism-based molecular subtyping and prognostic model
Neuroblastoma (NB) is recognized as the predominant extracranial malignant solid tumor in children and adolescent; the prognosis for high-risk patients remains poor. This limitation stems from its low mutational burden, an absence of antigen-presenting molecules, and vascular irregularities, which collectively impede immune cell infiltration, characterizing NB as a prototypical “cold tumor”. Intriguingly, metabolic pathways, especially through a novel glucose-dependent cellular death mechanism termed disulfidptosis and fatty acid metabolism (FAM), are pivotal in modulating the tumor’s energy dynamics and activating the tumor microenvironment (TME). Therefore, this study aims to explore the prognostic value and immunological implications of disulfidptosis-related fatty acid metabolism (DFAM) within the NB TME. To elucidate the implications of DFAM within the NB TME, this research included 971 NB patients. By using weighted gene co-expression network analysis (WGCNA), we constructed a prognostic risk score model based on DFAM, aimed at enhancing prognostication accuracy and informing therapeutic choices. The biological role of TFAP2D was validated in SK-N-AS and SK-N-BE2 cells via Cell Counting Kit-8 (CCK-8) assay, wound healing, and Transwell. Two distinct novel molecular subtypes were identified, revealing the correlations between DFAM and clinical-pathological features, prognostic outcomes, and TME infiltration patterns. The DFAM risk score model was established as an independent prognostic factor, correlated with immune cell infiltration and immunotherapeutic response. A novel discovery was the inhibitory effect of TFAP2D downregulation in NB cells on cellular survival, migration, and invasion. This research demonstrates that the crosstalk between DFAM and immune cells plays an important role in forming the “cold” TME of NB. The construction of DFAM-related score and the identification of a novel molecular subtype significantly contribute to the evolution of immunotherapeutic strategies. Furthermore, the discovery of TFAP2D as a metabolic driver of tumor progression provides a potential target to disrupt the metabolic plasticity of high-risk NB.
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 30
Open AccessTFAP2D drives neuroblastoma progression: a disulfidptosis-fatty acid metabolism-based molecular subtyping and prognostic model
Neuroblastoma (NB) is recognized as the predominant extracranial malignant solid tumor in children and adolescent; the prognosis for high-risk patients remains poor. This limitation stems from its low mutational burden, an absence of antigen-presenting molecules, and vascular irregularities, which collectively impede immune cell infiltration, characterizing NB as a prototypical “cold tumor”. Intriguingly, metabolic pathways, especially through a novel glucose-dependent cellular death mechanism termed disulfidptosis and fatty acid metabolism (FAM), are pivotal in modulating the tumor’s energy dynamics and activating the tumor microenvironment (TME). Therefore, this study aims to explore the prognostic value and immunological implications of disulfidptosis-related fatty acid metabolism (DFAM) within the NB TME. To elucidate the implications of DFAM within the NB TME, this research included 971 NB patients. By using weighted gene co-expression network analysis (WGCNA), we constructed a prognostic risk score model based on DFAM, aimed at enhancing prognostication accuracy and informing therapeutic choices. The biological role of TFAP2D was validated in SK-N-AS and SK-N-BE2 cells via Cell Counting Kit-8 (CCK-8) assay, wound healing, and Transwell. Two distinct novel molecular subtypes were identified, revealing the correlations between DFAM and clinical-pathological features, prognostic outcomes, and TME infiltration patterns. The DFAM risk score model was established as an independent prognostic factor, correlated with immune cell infiltration and immunotherapeutic response. A novel discovery was the inhibitory effect of TFAP2D downregulation in NB cells on cellular survival, migration, and invasion. This research demonstrates that the crosstalk between DFAM and immune cells plays an important role in forming the “cold” TME of NB. The construction of DFAM-related score and the identification of a novel molecular subtype significantly contribute to the evolution of immunotherapeutic strategies. Furthermore, the discovery of TFAP2D as a metabolic driver of tumor progression provides a potential target to disrupt the metabolic plasticity of high-risk NB.
- 26 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 23, 3741-3743
Corrigendum to 'Downregulation of ABLIM3 confers to the metastasis of neuroblastoma via regulating the cell adhesion molecules pathway' [Comput. Struct. Biotechnol. J., Vol. 23 (2024) 1547–1561]
[This corrects the article DOI: 10.1016/j.csbj.2024.04.024.].
- 26 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 23, 3741-3743
Corrigendum to 'Downregulation of ABLIM3 confers to the metastasis of neuroblastoma via regulating the cell adhesion molecules pathway' [Comput. Struct. Biotechnol. J., Vol. 23 (2024) 1547–1561]
[This corrects the article DOI: 10.1016/j.csbj.2024.04.024.].
- Open Access
- 10 July 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 177, 117126
Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2
- 10 July 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 177, 117126
Open AccessAnlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2
- Open Access
- 10 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 23, 1547-1561
Downregulation of ABLIM3 confers to the metastasis of neuroblastoma via regulating the cell adhesion molecules pathway
Neuroblastoma (NB) is the most prevalent extracranial solid tumor in pediatric patients, and its treatment failure often associated with metastasis. In this study, LASSO, SVM-RFE, and random forest tree algorithms, was used to identify the pivotal gene involved in NB metastasis. NB cell lines (SK-N-AS and SK-N-BE2), in conjunction with NB tissue were used for further study. ABLIM3 was identified as the hub gene and can be an independent prognostic factor for patients with NB. The immunohistochemical analysis revealed that ABLIM3 is negatively correlated with the metastasis of NB. Patients with low expression of ABLIM3 had a poor prognosis. High ABLIM3 expression correlated with APC co-stimulation and Type1 IFN response, and TIDE analysis indicated that patients with low ABLIM3 expression exhibited enhanced responses to immunotherapy. Downregulation of ABLIM3 by shRNA transfection increased the migration and invasion ability of NB cells. Gene Set Enrichment Analysis (GSEA) revealed that genes associated with ABLIM3 were primarily enriched in the cell adhesion molecules (CAMs) pathway. RT-qPCR and western blot analyses demonstrated that downregulation of ABLIM3 led to decreased expression of ITGA3, ITGA8, and KRT19, the key components of CAMs. This study indicated that ABLIM3 can be an independent prognostic factor for NB patients, and CAMs may mediate the effect of ABLIM3 on the metastasis of NB, suggesting that ABLIM3 is a potential therapeutic target for NB metastasis, which provides a novel strategy for future research and treatment strategies for NB patients.
- 10 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 23, 1547-1561
Open AccessDownregulation of ABLIM3 confers to the metastasis of neuroblastoma via regulating the cell adhesion molecules pathway
Neuroblastoma (NB) is the most prevalent extracranial solid tumor in pediatric patients, and its treatment failure often associated with metastasis. In this study, LASSO, SVM-RFE, and random forest tree algorithms, was used to identify the pivotal gene involved in NB metastasis. NB cell lines (SK-N-AS and SK-N-BE2), in conjunction with NB tissue were used for further study. ABLIM3 was identified as the hub gene and can be an independent prognostic factor for patients with NB. The immunohistochemical analysis revealed that ABLIM3 is negatively correlated with the metastasis of NB. Patients with low expression of ABLIM3 had a poor prognosis. High ABLIM3 expression correlated with APC co-stimulation and Type1 IFN response, and TIDE analysis indicated that patients with low ABLIM3 expression exhibited enhanced responses to immunotherapy. Downregulation of ABLIM3 by shRNA transfection increased the migration and invasion ability of NB cells. Gene Set Enrichment Analysis (GSEA) revealed that genes associated with ABLIM3 were primarily enriched in the cell adhesion molecules (CAMs) pathway. RT-qPCR and western blot analyses demonstrated that downregulation of ABLIM3 led to decreased expression of ITGA3, ITGA8, and KRT19, the key components of CAMs. This study indicated that ABLIM3 can be an independent prognostic factor for NB patients, and CAMs may mediate the effect of ABLIM3 on the metastasis of NB, suggesting that ABLIM3 is a potential therapeutic target for NB metastasis, which provides a novel strategy for future research and treatment strategies for NB patients.
- 23 March 2022
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1134) , 20211086
The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma
Objective: To retrospectively analyze radiotherapy (RT) regimens for patients with high-risk neuroblastoma (HRNB) at the primary site after surgery, and to further analyze the characteristics of patients who would benefit more from RT. Methods: 98 pediatric patients with HRNB were analyzed for local control (LC), RT dose, extent of excision and prognostic factors. Among them, 69 children received RT. Results: The 3 year LC rates were 96.9 and 62.1% (p < 0.001) in the RT and non-RT groups, respectively. In the non-RT group, LC was better in patients with complete macroscopic resection (CME) than in those with incomplete macroscopic resection (IME) (p = 0.026), while in the RT group, no significant difference in LC was found (p = 0.985). Among patients with IME, the LC was 100% in patients with RT doses >= 36 Gy and 66.7% in patients with doses <36 Gy. Conclusion: RT is valuable, provides patients with excellent LC, and is safe in the short term. RT had a complementary therapeutic effect on incompletely resected tumors, thus bringing their LC to the level of patients with CME. For patients with IME, RT at a dose of not less than 36 Gy may improve LC. Advances in knowledge: This study analysed the role of radiotherapy in HRNB, investigated the dose of RT depending on the degree of resection, and explored the characteristics of patients who would benefit more from RT.
- 23 March 2022
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1134) , 20211086
The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma
Objective: To retrospectively analyze radiotherapy (RT) regimens for patients with high-risk neuroblastoma (HRNB) at the primary site after surgery, and to further analyze the characteristics of patients who would benefit more from RT. Methods: 98 pediatric patients with HRNB were analyzed for local control (LC), RT dose, extent of excision and prognostic factors. Among them, 69 children received RT. Results: The 3 year LC rates were 96.9 and 62.1% (p < 0.001) in the RT and non-RT groups, respectively. In the non-RT group, LC was better in patients with complete macroscopic resection (CME) than in those with incomplete macroscopic resection (IME) (p = 0.026), while in the RT group, no significant difference in LC was found (p = 0.985). Among patients with IME, the LC was 100% in patients with RT doses >= 36 Gy and 66.7% in patients with doses <36 Gy. Conclusion: RT is valuable, provides patients with excellent LC, and is safe in the short term. RT had a complementary therapeutic effect on incompletely resected tumors, thus bringing their LC to the level of patients with CME. For patients with IME, RT at a dose of not less than 36 Gy may improve LC. Advances in knowledge: This study analysed the role of radiotherapy in HRNB, investigated the dose of RT depending on the degree of resection, and explored the characteristics of patients who would benefit more from RT.